The urge to do an IPO was strong, and for some, much too early. Maybe staying private before maturing is a good idea for companies, especially biotech ones. That’s...
Thanks to soaring corporate cash, capex has improved lately, but share repurchases still overshadow it.
Why big allocators on this side of the Atlantic, like CalSTRS, CPPIB, and OMERS, are seeding Old World newbie companies.
A quarter of the S&P 500’s rise since May is linked to positive developments on a virus inoculation, UBS says.